Fennec Pharmaceuticals Inc. (TSE:FRX) Director Rostislav Christov Raykov Sells 10,000 Shares

Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) Director Rostislav Christov Raykov sold 10,000 shares of the firm's stock in a transaction dated Thursday, July 3rd. The shares were sold at an average price of C$11.71, for a total transaction of C$117,096.00.

Rostislav Christov Raykov also recently made the following trade(s):

• On Thursday, June 5th, Rostislav Christov Raykov sold 10,000 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of C$10.66, for a total transaction of C$106,586.00.
• On Friday, May 16th, Rostislav Christov Raykov sold 16,667 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of C$9.49, for a total transaction of C$158,203.16.

Fennec Pharmaceuticals Stock Performance

Shares of FRX traded up C$0.27 on Friday, reaching C$12.16. The company's stock had a trading volume of 1,210 shares, compared to its average volume of 1,139. The company has a debt-to-equity ratio of -620.83, a current ratio of 7.80 and a quick ratio of 10.17. The stock has a market capitalization of C$234.50 million, a P/E ratio of -205.99 and a beta of 0.25. The stock's 50 day simple moving average is C$10.37 and its two-hundred day simple moving average is C$9.33. Fennec Pharmaceuticals Inc. has a 12-month low of C$5.65 and a 12-month high of C$12.16.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.